Within this research focus we bring together physio-pathology and therapeutic strategies for a variety of (bio)medical domains. To achieve this, in 2016 we established the Centre for inflammation and Therapeutic Innovation - or CiTI.
At present we hold two chairs of Arthritis Research UK, an Experimental Early Arthritis Treatment Centre, several large awards in musculoskeletal, hepatology, multiple sclerosis, gastrointestinal, dermatology and nephrology research. In addition, our inflammation strategy is to work together with bioengineering, nanomedicine and robotics scientists to maximise innovation and cross-fertilisation within Queen Mary University of London, and links with other ongoing research themes, including Dentistry and Trauma as well as diabetes.
The research aims to develop innovative therapeutic strategies, such as nutraceuticals and dietary approaches, human cell-driven target identification and validation.
Whilst a number of treatments are available for RA, none of them work for everyone and, currently, doctors have no way of telling which treatment will work best for which people with RA. The MATURA project, run by Barts and The London School of Medicine and Dentistry, QMUL, is to find and develop tests that will allow better targeting of the available treatments to those who would benefit most, thereby improving the selection of the best treatment for individual patients.
We have achieved major success in finding a cure for Hepatitis C, which was previously incurable, identifying lifesaving drug regimens for people with advanced Hepatitis C in liver failure. On-going work in the hepatology research strands focuses also on immunology of Hepatitis B and the etiopathogenesis of fatty liver disease.